Clinical Trials Directory

Trials / Unknown

UnknownNCT03866876

Eucapnic pH Compared With Arterial pH and Base Deficit

Umbilical Cord Arterial Eucapnic pH Compared With Arterial pH and Base Deficit as Predictor of Severe Adverse Outcomes Among Term Neonates

Status
Unknown
Phase
Study type
Observational
Enrollment
36,435 (estimated)
Sponsor
Hospices Civils de Lyon · Academic / Other
Sex
All
Age
Healthy volunteers
Not accepted

Summary

Neonatal asphyxia per partum can be complicated by severe neurologic sequelae and can lead to neonatal death. Of the 0.2% of live births to cerebral palsy, 10 to 28% would be secondary to neonatal acidosis. Only metabolic acidosis plays a neurotoxic role, explaining the recent interest of Racinet et al. in the development of a new biochemical marker, more specific than pH or base deficit, of neonatal asphyxia per partum at risk of anoxo-ischemic encephalopathy. This eucapnic neonatal pH raises the hope of a biochemical marker of situations at risk of poor prognosis, with high diagnostic value, prognostic and forensic. Our hypothesis is that eucapnic pH is more efficient than cord blood arterial pH and base deficit in the prediction of adverse neurologic outcomes.

Conditions

Interventions

TypeNameDescription
OTHEREucapnic pHCollection of Biological marker (proposed by Racinet): eucapnic pH

Timeline

Start date
2018-09-01
Primary completion
2019-04-01
Completion
2019-04-01
First posted
2019-03-07
Last updated
2019-03-07

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT03866876. Inclusion in this directory is not an endorsement.